Product

Furosemide Zdorovye

1 form: solution. In force in Georgia: 1 of 1 (human register).

Forms and doses1 of 1 in force in Georgia

Form	Dose	Frequency	Georgia
10 mg/ml, Solution	No label dose in the reference yet	-	Georgia Yes, human In force until 13 Aug 2031 Human (Ministry of Health, RAMA) In the register: ფუროსემიდი ზდოროვიე 10 მგ/მლ, 2 მლ ამპულა, საინექციო ხსნარი № რ-046153 mis.ge (Ministry of Health register incl. past registrations) Verified on: 16 Oct 2026
Details: pack, label wording, sources, registration Furosemide Zdorovye 10 mg/ml, Solution 2 ml ampoule, solution for injection, human medicine vetman assessment vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient. Dog Off-label injectable furosemide for rapid hospital treatment of clinically confirmed oedema or volume overload in dogs, especially acute congestive heart failure, with response-guided dosing and monitoring 6.9/10 Situational / acceptable vetman assessment Furosemide Zdorovye 10 mg/ml, 2 ml ampoule, solution for injection, human medicine Assessed clinical scopeDog · Off-label injectable furosemide for rapid hospital treatment of clinically confirmed oedema or volume overload in dogs, especially acute congestive heart failure, with response-guided dosing and monitoring · IV,IM Care settingVeterinary hospital or emergency care with route-appropriate aseptic administration, oxygen or drainage when indicated, and close cardiorespiratory, renal, electrolyte and hydration monitoring vetman score 6.9/10 Situational / acceptable Evidence confidence: Medium Georgia: Yes, human · № რ-046153 · Verified on 16 Oct 2026 Off-label use A strong acute-care furosemide platform in a practical concentration, but exact-brand use is off-label and safe benefit depends on diagnosis, route, repeated response assessment and kidney/electrolyte monitoring. Regulatory and scientific credibility6.0/10 The exact 10 mg/ml human ampoule is currently registered in Georgia, but no current exact trade-name match was found in the checked EU, UK or US registers. An authorised EU veterinary 10 mg/ml injectable product supports the formulation, while this exact product remains off-label. Clinical efficacy8.5/10 Guidelines make parenteral furosemide a central treatment for acute canine CHF and pulmonary oedema; veterinary injectable labels, a 30-dog acute study, a 100-pet hospital series and renal-outcome data give direct support. Bolus and CRI strategies both work, but neither is universally superior. Safety and tolerability6.0/10 Rapid parenteral diuresis is well characterised but can produce dehydration, hypotension, azotaemia and electrolyte loss; a canine hospital cohort documents kidney injury risk and the 100-pet series found greater creatinine and protein rises with CRI. Dose and route require close reassessment. Clinical practicality7.5/10 The 10 mg/ml concentration permits straightforward weight-based measurement and IV or IM use, but each ampoule contains only 20 mg, so larger dogs or a CRI may require multiple ampoules, dilution and venous access. This is a clinician-administered hospital presentation. Full-course cost-effectiveness- Price was not assessed and is excluded from the overall score. Important safety and use flags Do not use in anuria, severe hypovolaemia or dehydration, marked electrolyte depletion, or acute glomerular nephritis without resolving the underlying state. Avoid concurrent aminoglycosides where possible and review every nephrotoxic or ototoxic medicine; rapid high exposure can compound renal or auditory injury. Record renal values, sodium, potassium and chloride before treatment when the emergency permits and recheck promptly after substantial parenteral exposure. Track respiratory effort and rate, oxygenation, body weight, blood pressure, urine output, hydration and congestion; stop escalating when the clinical target is reached. NSAIDs can blunt diuresis and worsen renal risk; ACE inhibitors, other diuretics and vasodilators can amplify hypotension or azotaemia, while hypokalaemia can increase cardiac-glycoside toxicity. A constant-rate infusion is not automatically safer than boluses; published hospital data found greater creatinine and total-protein rises with CRI, so choose and reassess the strategy clinically. Confirm the ampoule concentration as 10 mg/ml, calculate both mg/kg and ml, use aseptic technique and discard any unvalidated remainder; several ampoules may be needed for large dogs or CRI preparation. Use only the exact product-labelled IV or IM routes. Do not infer subcutaneous use from a different veterinary furosemide product, and verify dilution, compatibility and administration rate before IV use. Safety in pregnancy and lactation is not established for these exact products; use only after individual benefit-risk assessment, noting that intense diuresis can reduce lactation. Assessment sources Georgia injectable furosemide register2026 EU DIUREN 10 mg/ml2026 FDA furosemide injection2002 MSD Vet Manual diuretics2026 Acute CHF IV furosemide 20182018 ACVIM canine MMVD2019 Dog acute furosemide 20162016 Dog parenteral furosemide kidney injury2022 Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised. Cat Off-label injectable furosemide for rapid hospital treatment of clinically confirmed oedema or volume overload in cats, especially acute congestive heart failure, with response-guided dosing and monitoring 7.0/10 Good vetman assessment Furosemide Zdorovye 10 mg/ml, 2 ml ampoule, solution for injection, human medicine Assessed clinical scopeCat · Off-label injectable furosemide for rapid hospital treatment of clinically confirmed oedema or volume overload in cats, especially acute congestive heart failure, with response-guided dosing and monitoring · IV,IM Care settingVeterinary hospital or emergency care with route-appropriate aseptic administration, oxygen or drainage when indicated, and close cardiorespiratory, renal, electrolyte and hydration monitoring vetman score 7.0/10 Good Evidence confidence: Medium Georgia: Yes, human · № რ-046153 · Verified on 16 Oct 2026 Off-label use A practical concentration for feline emergency dosing with a central CHF role, but exact-brand use is off-label and must remain hospital-directed with rapid response, renal, electrolyte and hydration reassessment. Regulatory and scientific credibility6.0/10 The exact 10 mg/ml human ampoule is currently registered in Georgia, but no current exact trade-name match was found in the checked EU, UK or US registers. An authorised EU veterinary 10 mg/ml injectable product supports the formulation, while this exact product remains off-label. Clinical efficacy8.0/10 Guidelines recommend intravenous furosemide for feline CHF with pulmonary oedema, and authorised injectable labels, direct feline IV PK data and a 100-pet acute hospital series support rapid decongestion. Much of the feline regimen evidence remains consensus or retrospective rather than large controlled trials. Safety and tolerability6.0/10 Rapid parenteral diuresis is well characterised but can produce dehydration, hypotension, azotaemia and electrolyte loss. Cats with CHF commonly develop azotaemia, while acute bolus or CRI treatment requires close respiratory, renal, electrolyte, hydration and blood-pressure reassessment. Clinical practicality8.5/10 The 10 mg/ml concentration and 2 ml ampoule permit accurate small feline volumes and IV or IM administration without tablet splitting. Venous access, asepsis, patient stress and rapid-diuresis monitoring still make this a clinician-administered hospital presentation. Full-course cost-effectiveness- Price was not assessed and is excluded from the overall score. Important safety and use flags Do not use in anuria, severe hypovolaemia or dehydration, marked electrolyte depletion, or acute glomerular nephritis without resolving the underlying state. Avoid concurrent aminoglycosides where possible and review every nephrotoxic or ototoxic medicine; rapid high exposure can compound renal or auditory injury. Record renal values, sodium, potassium and chloride before treatment when the emergency permits and recheck promptly after substantial parenteral exposure. Track respiratory effort and rate, oxygenation, body weight, blood pressure, urine output, hydration and congestion; stop escalating when the clinical target is reached. NSAIDs can blunt diuresis and worsen renal risk; ACE inhibitors, other diuretics and vasodilators can amplify hypotension or azotaemia, while hypokalaemia can increase cardiac-glycoside toxicity. A constant-rate infusion is not automatically safer than boluses; published hospital data found greater creatinine and total-protein rises with CRI, so choose and reassess the strategy clinically. Confirm the ampoule concentration as 10 mg/ml, calculate both mg/kg and ml, use aseptic technique and discard any unvalidated remainder; several ampoules may be needed for large dogs or CRI preparation. Use only the exact product-labelled IV or IM routes. Do not infer subcutaneous use from a different veterinary furosemide product, and verify dilution, compatibility and administration rate before IV use. Safety in pregnancy and lactation is not established for these exact products; use only after individual benefit-risk assessment, noting that intense diuresis can reduce lactation. Assessment sources Georgia injectable furosemide register2026 EU DIUREN 10 mg/ml2026 FDA furosemide injection2002 MSD Vet Manual diuretics2026 Acute CHF IV furosemide 20182018 ACVIM feline cardiomyopathy2020 Cat furosemide PK 20192019 Feline CHF azotemia 20252025 Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised. Composition / strength Furosemide10 mg/ml Formulation Type Solution Administration route Intravenous, Intramuscular Manufacturer Zdorovye · Ukraine Registration Georgia Yes, human In force until 13 Aug 2031 Human (Ministry of Health, RAMA) In the register: ფუროსემიდი ზდოროვიე 10 მგ/მლ, 2 მლ ამპულა, საინექციო ხსნარი № რ-046153 mis.ge (Ministry of Health register incl. past registrations) Verified on: 16 Oct 2026 EU No EMA Article 57 database (all medicines authorised in the EU/EEA), 09.10.2026 Verified on: 16 Oct 2026 UK No MHRA Products (UK) Verified on: 16 Oct 2026 US No Drugs@FDA (openFDA) Verified on: 16 Oct 2026 Controlled in Georgia No Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n. matsne.gov.ge Verified on: 16 Oct 2026

Active substance doses, with sources

Each dose comes with its source. Check the label of the product you use.

Active substance Furosemide

Dose calculatorCalculates the active-substance amount; it is not a prescription.

PatientSpecies and weight will be filled in automatically in other calculators.

Species Weight (kg)

Indication

Selected dose

Product presentation

Dose	Species	Indication	Route	Frequency	Source
2.5–5 mg/kg	Dog, Cat	Maintenance	By mouth	once daily	VMD SPC 2026 Official product label (SPC), VMD, UK Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there. Furosoral 10 mg Tablets for Cats and Dogs - Summary of Product Characteristics UK Veterinary Medicines Directorate, 2026 Open the source ↗
2 mg/kg	Dog	Congestive Heart Failure	By mouth	2 times daily	ACVIM canine MMVD Guideline or consensus statement Recommendations agreed by a panel of veterinary specialists after reviewing the evidence. They guide practice and do not authorise a product. ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs Journal of Veterinary Internal Medicine, 2019 Open the source ↗
1–2 mg/kg	Dog, Cat	Maintenance	Intravenous	every 6-8 hours	VMD SPC 2025 Official product label (SPC), VMD, UK Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there. Dimazon 50 mg/ml Solution for Injection - Summary of Product Characteristics UK Veterinary Medicines Directorate, 2025 Open the source ↗
5 mg/kg	Dog, Cat	Loading	Intravenous	once, as the first dose	VMD SPC 2025 Official product label (SPC), VMD, UK Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there. Dimazon 50 mg/ml Solution for Injection - Summary of Product Characteristics UK Veterinary Medicines Directorate, 2025 Open the source ↗
2 mg/kg off-label	Dog	Congestive Heart Failure Emergency	Intravenous	every hour, to a maximum total of 8 mg/kg over 4 hours	ACVIM canine MMVD Guideline or consensus statement Recommendations agreed by a panel of veterinary specialists after reviewing the evidence. They guide practice and do not authorise a product. ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs Journal of Veterinary Internal Medicine, 2019 Open the source ↗
0.5–2 mg/kg	Cat	Congestive Heart Failure	By mouth	every 8-12 hours	ACVIM feline cardiomyopathy Guideline or consensus statement Recommendations agreed by a panel of veterinary specialists after reviewing the evidence. They guide practice and do not authorise a product. ACVIM consensus statement guidelines for the classification, diagnosis, and management of cardiomyopathies in cats Journal of Veterinary Internal Medicine, 2020 Open the source ↗
1–2 mg/kg	Cat	Congestive Heart Failure Emergency	Intravenous	as repeated boluses	ACVIM feline cardiomyopathy Guideline or consensus statement Recommendations agreed by a panel of veterinary specialists after reviewing the evidence. They guide practice and do not authorise a product. ACVIM consensus statement guidelines for the classification, diagnosis, and management of cardiomyopathies in cats Journal of Veterinary Internal Medicine, 2020 Open the source ↗

Known Contraindications

Critical
Do not use in animals suffering from hypovolaemia, hypotension or dehydration. Do not use in cases of electrolyte deficiency.

Sources: VMD SPC · VMD
Critical
Do not use in cases of renal failure with anuria. Do not use in acute glomerular nephritis.

Sources: VMD SPC · VMD
Critical
Do not use in cases of hypersensitivity to furosemide, sulphonamides or to any of the excipients. Furosemide may increase the risk of sulfonamide cross-reactivity.

Sources: VMD SPC · VMD
Warning
Furosemide should be used with caution in the case of pre-existing electrolyte and/or water imbalance, impaired hepatic function (may precipitate hepatic coma) and diabetes mellitus.

Sources: VMD SPC · VMD
Warning
Furosemide may alter insulin requirements in diabetic animals.

Sources: VMD SPC · VMD
Warning
Laboratory studies have shown evidence of teratogenic effects. The safety of the veterinary medicinal product has not been established during pregnancy or lactation.

Sources: VMD SPC · VMD
Warning
However furosemide is excreted into milk... A deleterious effect on lactation is to be expected, particularly if drinking water is restricted.

Sources: VMD SPC · VMD

Known Drug Interactions

Contraindicated Furosemide + Dihydrostreptomycin
Do not use concurrently with aminoglycoside antibiotic treatment. In cats, do not use furosemide with ototoxic antibiotics. Concomitant use with aminoglycosides or cephalosporins may increase the risk of nephrotoxicity.

Recommendation: Do not administer concurrently. If an aminoglycoside is essential, choose a diuretic from another class.

Sources: VMD SPC · VMD
Contraindicated Furosemide + Torasemide
Do not use concomitantly with other loop diuretics.

Recommendation: Substitute one for the other rather than adding them. A single torasemide dose is approximately 20 times as potent as a single furosemide dose in the pharmacodynamic model, so milligrams are not directly interchangeable.

Sources: VMD SPC · VMD
Major warning Furosemide + Ceftriaxone
Concomitant use with aminoglycosides or cephalosporins may increase the risk of nephrotoxicity.

Recommendation: Monitor renal parameters and hydration. Avoid the combination in a dehydrated patient.

Sources: VMD SPC · VMD
Major warning Furosemide + Prednisolone
Concurrent use with drugs affecting electrolyte balance (corticosteroids, other diuretics, amphotericin B, cardiac glycosides) requires careful monitoring.

Recommendation: Monitor electrolytes, particularly potassium. Check periodically during prolonged combination therapy.

Sources: VMD SPC · VMD
Minor warning Furosemide + Amlodipine
Concomitant use of amlodipine with other agents that may reduce blood pressure may cause hypotension. These agents include: diuretics, beta-blockers, other calcium channel blockers, inhibitors of the renin angiotensin aldosterone system... and alpha-2 agonists. may sometimes result in a decrease in serum potassium and chloride levels

Recommendation: Before combining amlodipine with these agents, measure blood pressure and ensure that the cat is adequately hydrated. Monitor electrolytes and hydration during treatment.

Sources: VMD SPC · VMD · IRIS
Minor warning Furosemide + Dexamethasone
The risk of hypokalaemia may be increased if dexamethasone is administered together with potassium depleting diuretics.

Recommendation: Monitor serum potassium. Hypokalaemia also increases cardiac glycoside toxicity.

Sources: VMD SPC · VMD
Minor warning Robenacoxib + Furosemide
When robenacoxib is used with drugs that affect renal blood flow, such as diuretics or angiotensin-converting enzyme inhibitors, monitor the patient clinically.

Recommendation: Monitor the patient clinically and check renal parameters.
Minor warning Furosemide + Levothyroxine
Several drugs, including barbiturates, antacids, anabolic steroids, diazepam, and furosemide, can alter thyroid-hormone binding or metabolism and may affect the response to levothyroxine.

Recommendation: Recheck T4 and adjust the dose as needed.

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 16 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Furosemide Zdorovye

Forms and doses1 of 1 in force in Georgia